Skip to main content

Table 3 Currently accruing or upcoming clinical trials in anatomy-adapted adaptive radiotherapy (A-ART)

From: Adaptive radiotherapy for head and neck cancer

Clinical Trial Primary Investigator
Description Eligible Target Accrual
(Actual or Current Accrual)
Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy (GIRAFE) [45, 60] Laprie Anne
(Institut Universitaire Du Cancer Toulouse, Oncopole, France)
Prospective phase II trial evaluating the accuracy of deformable image registration on daily MV-CTs. Deformable image registration will be compared to manual recontouring on weeks 3, 4, 5, and 6.
Primary Outcome: Dice similarity coefficient
Implication: if deformable image registration is reliable, may help streamline A-ART and assist with identification of those who would benefit
T3–4 and/or node > 2 cm HNSCC receiving definitive RT 48 Not yet recruiting (as of July 25, 2019)
A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy [45] Jillian Tsai, MD
(Memorial Sloan Kettering Cancer Center)
Prospective trial comparing LRFS in those receiving ART to historical controls with the intent of assessing non-inferiority
Primary Outcome: LRFS at 2 years
HNSCC receiving definitive RT 65 [61] Active, not recruiting (as of May 27, 2019)
MRI-guided Adaptive RadioTHerapy for reducing xerostomiA in Head and Neck Cancer (MARTHA-trial) [50] Panagiotis Balermpas, MD
(University Hospital Zurich)
Prospective trial of MRI-guided IGRT with daily MRI imaging and weekly plan adaptation, with the objective of evaluating xerostomia by LENT-SOMA and salivary flow measurements at baseline, 6, 12, and 24 months
Primary Outcome: 12 month grade 2 or worse xerostomia
Stages II-IVb HNSCC receiving definitive RT 44 Not yet recruiting